Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label trial of oral budesonide 9 mg in active ulcerative colitis
2014-005635-14Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Feb 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of budesonide in autoimmune colitis, sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Clinical remission rate at final/withdrawal visit. Started Feb 2015; status: completed.
02
Drugs
budesonide
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2014-005635-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005635-14.